Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Reckitt trumps Bayer with $1.4 billion bid for Schiff

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2012 | 03:07pm CEST

Reckitt Benckiser Group Plc (>> Reckitt Benckiser Group Plc) has trumped Bayer AG's (>> Bayer AG) agreed deal to buy Schiff Nutrition International Inc (>> Schiff Nutrition International Inc) with a higher offer of $1.4 billion for the U.S. vitamin maker.

Reckitt Benckiser Group Plc (>> Reckitt Benckiser Group Plc) has trumped Bayer AG's (>> Bayer AG) agreed deal to buy Schiff Nutrition International Inc (>> Schiff Nutrition International Inc) with a higher offer of $1.4 billion for the U.S. vitamin maker.

The bid, which tops Bayer's $1.2 billion price, opens up a potential bidding war for Schiff, whose portfolio of vitamins and nutritional supplements, such as MegaRed for heart care and Move Free for joints, is attractive to companies seeking stable sources of growth.

Reckitt, the British consumer products group behind Cillit Bang cleaner and Durex condoms, said late on Thursday it would offer $42 in cash for each Schiff share, a 23.5 percent premium over the $34 per share that Bayer, Germany's biggest drugmaker, agreed to pay on October 30.

Shares of Schiff Nutrition surged nearly 30 percent to $44 in after-hours trading on the New York Stock Exchange, above Reckitt's offer and indicating some investors expect the bidding to go higher still.

Reckitt commenced a tender offer on Friday and said it would expire at 9:00 a.m. New York time on December 14, unless extended.

The new offer values Schiff at about 3.6 times its forecast 2013 annual sales, which is around the top end of deal multiples in the non-prescription drugs industry.

But it would get Reckitt into the $30 billion global market for vitamins and supplements for the first time, complementing its existing strength in other areas of consumer health.

"When this offer was made by Bayer - which was a bilateral agreement and not a public auction process - we knew that this was an area we would be very interested in," Reckitt Chief Executive Officer Rakesh Kapoor told Reuters.

"That's why we started to work and look at it once again to see whether this would be attractive to our shareholders. Based on our due diligence, we believe it is and that's why we've come up with a strong offer."

Analyst Andrew Wood at brokerage Bernstein said the deal made good strategic sense for Reckitt.

"This is particularly true given (Reckitt's) ... excellent M&A track record and its ability to quickly extract big synergies from acquired companies," he said.

Its past deals in the health sector include buying Boots' over-the-counter business in 2006 for 1.9 billion pounds ($3.0 billion), cough medicines company Adams in 2008 for $2.3 billion and Durex condoms group SSL for 2.5 billion pounds in 2010.


Reckitt said it expected the deal to boost earnings immediately on an adjusted basis and Bernstein's Wood predicted an uplift of about 1 to 2 percent in 2013 earnings per share.

A Bayer spokesman declined to comment and representatives for Schiff could not be immediately reached for comment.

While Bayer may bide its time before reacting to Reckitt's move, its management will be under pressure to salvage a deal that was well received by investors.

"A bidding war cannot be ruled out. Bayer probably has to match the Reckitt offer. This would result in an acquisition price which might get unattractive for Bayer," DZ Bank analyst Peter Spengler said in a research note.

Bayer shares were 1.3 percent higher by 1400 GMT, while Reckitt dipped 0.7 percent.

Under the terms of its deal with Bayer, Schiff is allowed to entertain superior offers made in writing before November 28. If it decides to go with another offer, it would have to pay a relatively modest $22 million breakup fee to Bayer.

With Schiff now in play, analysts said the situation could also attract interest from other parties - in particular Johnson & Johnson (>> Johnson & Johnson), the only other leading consumer health player lacking a presence in vitamins and supplements.

Schiff Chairman Eric Weider and private equity firm TPG Capital controlled 85 percent of the company's voting power, as of the end of October.

For Bayer, the planned acquisition of Schiff represents part of a strategy to expand into steadier, albeit less profitable, areas as a counterweight to prescription medicines, where there are high risks of clinical trial failures and patent expiries.

Reckitt, meanwhile, is keen to build up its healthcare business, which already includes painkillers, anti-acne creams and condoms. It also makes a range of household and personal care products.

Morgan Stanley is acting as financial adviser to Reckitt, while Houlihan Lokey is advising Schiff alongside Rothschild. Bayer is being advised by Bank of America Merrill Lynch. ($1 = 0.6300 British pounds)

(Additional reporting by Soyoung Kim, Ludwig Burger, Anjuli Davies and Zeba Siddiqui; editing by Sriraj Kalluvila and David Holmes)

By Michael Erman and Ben Hirschler

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
10/19 BAYER : Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enha..
10/19 BAYER : submits its extended half - life hemophilia a compound for marketing aut..
10/18 BAYER : to fund three youth-led food security projects
10/17 BAYER : foundations bring tech pioneers physicians and social entrepreneurs to t..
10/16 BAYER : Health and Human Services Department (HHS); Food and Drug Administration..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
10/13 Bayer sells units to be able to complete Monsanto takeover
10/13 BAYER : foundations bring tech pioneers, physicians and social entrepreneurs to ..
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/17 Monsanto Ending On A Position Of Strength
10/16 BASF (BASFY) To Acquire Significant Parts Of Bayer's (BAYZF) Seed And Non-Sel..
10/14 BASF Buys Bayer's Crop Science Assets At A Fair Price
10/13 WALL STREET BREAKFAST : The Beat Goes On For Global Stocks As Records Continue T..
Financials (€)
Sales 2017 47 846 M
EBIT 2017 9 231 M
Net income 2017 5 397 M
Debt 2017 12 235 M
Yield 2017 2,35%
P/E ratio 2017 19,41
P/E ratio 2018 17,59
EV / Sales 2017 2,29x
EV / Sales 2018 2,19x
Capitalization 97 538 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121 €
Spread / Average Target 2,6%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER18.99%114 930
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116